prompt string | completion string | split string | pair_id string | ranking_query_id string | ranking_member_index int64 | ranking_candidate_row_count int64 | ranking_candidate_parent_count int64 | retrieval_parent_rank int64 | retrieval_parent_context_index int64 | retrieval_parent_context_count int64 | task_id string | source_id string | retrieval_strategy string | query_record_id string | retrieval_record_id string | query_benchmark_row_id string | retrieval_benchmark_row_id string | query_molecule_identity_key string | retrieval_molecule_identity_key string | query_smiles string | retrieval_smiles string | query_condition_group string | retrieval_condition_group string | query_condition_scope string | retrieval_condition_scope string | query_condition_atoms list | retrieval_condition_atoms list | candidate_context_relation string | query_source_record_count int64 | retrieval_source_record_count int64 | query_agreement_fraction float64 | retrieval_agreement_fraction float64 | query_gold_Y int64 | retrieval_gold_Y int64 | ranking_balance_label string | query_geometry_value float64 | retrieval_geometry_value float64 | absolute_geometry_difference float64 | calibration_sample_standard_deviation float64 | target_distribution dict | canonical_endpoint_key string | assay_concept string | measurement_kind string | metadata dict | absolute_canonical_value_difference float64 | standardized_canonical_value_difference float64 | sd_logistic_similarity float64 | target_train_sample_standard_deviation float64 | target_a float64 | target_b float64 | label_mode string | binary_label int64 | is_decisive bool | morgan_tanimoto_similarity float64 | graph_a_position int64 | graph_b_position int64 | graph_offset int64 | representation string | pair_bucket_key string | query_parent_id string | retrieval_parent_id string | query_scaffold string | retrieval_scaffold string | query_evidence dict | retrieval_evidence dict | bucket_total_record_count int64 | bucket_train_record_count int64 | bucket_train_parent_count int64 | evaluation_regime string | calibration_scope string | logit_geometry_transform string | query_source_payload_json string | retrieval_source_payload_json string | level string | level_family string | query_source_row_uid string | retrieval_source_row_uid string | upstream_pair_bucket_key string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CC(C)COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C#N)c(N[C@H]2[C@@H](C(N)=O)[C@@H]3C=C[C@H]2C3)n1</SMILES>
- Assay interpretation conditions: Reference compound comparator within the same... | (B) | train | ac803ebfb287559a0b20fda62b101efb388894353d3d08c0f453118593deed1b | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:7e296e9363750f24fbdea0cde622ccdcc0e2b7123ddb58fc8773ed7888c0dbd8 | carcinogens:4e7e7a0439fe575a8eed23fcd83ad69079a8966af8f9cfc7092529a908e4ed0c | carcinogens:7e296e9363750f24fbdea0cde622ccdcc0e2b7123ddb58fc8773ed7888c0dbd8 | carcinogens:4e7e7a0439fe575a8eed23fcd83ad69079a8966af8f9cfc7092529a908e4ed0c | WVUNYSQLFKLYNI-AATRIKPKSA-N | UXBPLRFFIZKKDS-SMABIVBASA-N | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C | CC(C)COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C#N)c(N[C@H]2[C@@H](C(N)=O)[C@@H]3C=C[C@H]2C3)n1 | ["carcinogens_v1","proliferation or DNA synthesis","nM","__unknown__","cell growth inhibition assay (IC50)","L3"] | ["carcinogens_v1","proliferation or DNA synthesis","nM","__unknown__","cell growth inhibition assay (IC50)","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=Cell proliferation inhibition assay with IC50 determination in tissue culture",
"biological_test_system=MCF-7 breast carcinoma cell line; in-vitro tissue culture; Homo sapiens; low EGF-R expression",
"canonical_assay_context=cell growth inhibition assay (IC50)",
"canonical_measurement_scale_id=_... | [
"assay_interpretation_conditions=Reference compound comparator within the same four-cell-line panel.",
"assay_method=Antiproliferative growth inhibition assay (IC50 determination)",
"biological_test_system=JHH7 hepatocellular carcinoma cell line, Homo sapiens",
"canonical_assay_context=cell growth inhibition ... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 3.556303 | 2.450249 | 1.106053 | 1.035632 | {
"nontransfer": 0.9987457801937603,
"transfer": 0.0012542198062396885
} | ["carcinogens_v1","proliferation or DNA synthesis","nM","__unknown__","cell growth inhibition assay (IC50)","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"proliferation or DNA synthesis\",\"nM\",\"__unknown__\",\"cell growth inhibition assay (IC50)\"... | 3,318 | 1.067999 | 0.001254 | 1.035632 | 0.001254 | 0.998746 | safety_canonical_v27 | 0 | true | 0.245763 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","proliferation or DNA synthesis","nM","__unknown__","cell growth inhibition assay (IC50)","L3"] | WVUNYSQLFKLYNI-AATRIKPKSA-N | UXBPLRFFIZKKDS-SMABIVBASA-N | c1ccc(Nc2ccnc3ccccc23)cc1 | C1=CC2CC1CC2Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "3600",
"display_unit_text": "nM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 3600,
"aggregate_max": 3600,
"aggregate_q1": 3600,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "282",
"display_unit_text": "nM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 282,
"aggregate_max": 282,
"aggregate_q1": 282,
"aggregate_q3":... | 280 | 273 | 177 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":null,"assay_method":"Cell proliferation inhibition assay with IC50 determination in tissue culture","biological_test_system":"MCF-7 breast carcinoma cell line; in-vitro tissue culture; Homo sapiens; low EGF-R expression","canonical_assay_context":"cell growth inhibition assay (IC50)",... | {"assay_interpretation_conditions":"Reference compound comparator within the same four-cell-line panel.","assay_method":"Antiproliferative growth inhibition assay (IC50 determination)","biological_test_system":"JHH7 hepatocellular carcinoma cell line, Homo sapiens","canonical_assay_context":"cell growth inhibition assa... | L3 | gold_v1 | sr_a2d1e5ea1521406e9214a07802305112 | sr_b5fae9d001fb4f909084119d53b96795 | ["carcinogens_v1","proliferation or DNA synthesis","nM","__unknown__","cell growth inhibition assay (IC50)"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CCOC(=O)c1ccc(NC(=O)CSC(CC(=O)c2sc(Nc3ccccn3)nc2C)c2ccccc2F)cc1</SMILES>
- Assay interpretation conditions: IC50 reported as M ± SD.
- Assay method: MTT reduction assay, IC50 de... | (B) | train | 3304e535e1f8325ab5d13022f0496d5c6006759ed5f1106fcf3e3c10e94b70f4 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:06107420a05a165b92e74a6ecf0a50a0c8eb349cb65426ad072a190946925c32 | carcinogens:783c3a6b2b77ad603c04d5e64533ad740b36afb3e03765824d6a6440bbf7fe7a | carcinogens:06107420a05a165b92e74a6ecf0a50a0c8eb349cb65426ad072a190946925c32 | carcinogens:783c3a6b2b77ad603c04d5e64533ad740b36afb3e03765824d6a6440bbf7fe7a | WHZWWLCYXHEKOB-UHFFFAOYSA-N | RTRVDZMQJAKYQV-UHFFFAOYSA-N | CCOC(=O)c1ccc(NC(=O)C(c2ccccc2)N(C(=O)c2ccccc2C)c2ccccc2)cc1 | CCOC(=O)c1ccc(NC(=O)CSC(CC(=O)c2sc(Nc3ccccn3)nc2C)c2ccccc2F)cc1 | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=MTT microculture reduction assay",
"biological_test_system=WI-38 normal fibroblast cell line, human, in vitro",
"canonical_assay_context=MTT assay (IC50)",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50 for inhibition of cell viability",
"endpoint_name=cell_viability_or... | [
"assay_interpretation_conditions=IC50 reported as M ± SD.",
"assay_method=MTT reduction assay, IC50 determination",
"biological_test_system=HCT-116 colon cancer cell line, human, in vitro",
"canonical_assay_context=MTT assay (IC50)",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50 (co... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 0.123525 | 0.786041 | 0.662516 | 0.864106 | {
"nontransfer": 0.9750853132022578,
"transfer": 0.024914686797742187
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"MTT assay (IC50)\",\"L3\"]",
"q... | 4.781 | 0.766707 | 0.024915 | 0.864106 | 0.024915 | 0.975085 | safety_canonical_v27 | 0 | true | 0.290323 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | WHZWWLCYXHEKOB-UHFFFAOYSA-N | RTRVDZMQJAKYQV-UHFFFAOYSA-N | O=C(Nc1ccccc1)C(c1ccccc1)N(C(=O)c1ccccc1)c1ccccc1 | O=C(CSC(CC(=O)c1cnc(Nc2ccccn2)s1)c1ccccc1)Nc1ccccc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "1.329",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 1.329,
"aggregate_max": 1.329,
"aggregate_q1": 1.329,
"aggreg... | {
"aggregation_method": "individual_record",
"display_measurement_text": "6.11",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 6.11,
"aggregate_max": 6.11,
"aggregate_q1": 6.11,
"aggregate_... | 1,392 | 1,368 | 880 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":null,"assay_method":"MTT microculture reduction assay","biological_test_system":"WI-38 normal fibroblast cell line, human, in vitro","canonical_assay_context":"MTT assay (IC50)","canonical_measurement_scale_id":"__unknown__","confidence":0.9,"effect_direction":"decreased","endpoint_me... | {"assay_interpretation_conditions":"IC50 reported as M \u00b1 SD.","assay_method":"MTT reduction assay, IC50 determination","biological_test_system":"HCT-116 colon cancer cell line, human, in vitro","canonical_assay_context":"MTT assay (IC50)","canonical_measurement_scale_id":"__unknown__","confidence":0.93,"effect_dir... | L3 | gold_v1 | sr_b282333c73b14c37974b14b142af774e | sr_940539057d7d48df8901d62f02358fc1 | ["carcinogens_v1","cell viability or survival","µM","__unknown__","MTT assay (IC50)"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>COc1cc([C@@H]2c3cc4c(cc3[C@@H](NC(=S)Nc3ccc(C(C)C)cc3)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC</SMILES>
- Assay interpretation conditions: Cytotoxicity/viability endpoint.
- Assay m... | (B) | train | fd2c93d852a04f3ff91eaa4c2ac7be533f9f812c8fe73819eeb4e11b8573884c | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:b93280278022b45e6438eab5fe665d87e53563840f8872bc2631ba83e4afb8f6 | carcinogens:f84a762fa82aba7a73e26461459192c7ba3599fc6767bfcb4e288d553337db90 | carcinogens:b93280278022b45e6438eab5fe665d87e53563840f8872bc2631ba83e4afb8f6 | carcinogens:f84a762fa82aba7a73e26461459192c7ba3599fc6767bfcb4e288d553337db90 | WXDCPCOGKPVYIN-QNMIOERPSA-N | ZNGCDWOWEZBNJC-ALMBTRMVSA-N | COc1cc([C@@H]2c3cc4c(cc3[C@@H](NC(=S)Nc3ccc([N+](=O)[O-])cc3)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC | COc1cc([C@@H]2c3cc4c(cc3[C@@H](NC(=S)Nc3ccc(C(C)C)cc3)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT cell viability/proliferation IC50","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT cell viability/proliferation IC50","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Cytotoxicity/viability endpoint.",
"assay_method=MTT colorimetric assay, IC50 determination",
"biological_test_system=DU-145 human prostate cancer cell line, in vitro, Homo sapiens",
"canonical_assay_context=MTT cell viability/proliferation IC50",
"canonical_measurement_scal... | [
"assay_interpretation_conditions=Cytotoxicity/viability endpoint.",
"assay_method=MTT colorimetric assay, IC50 determination",
"biological_test_system=DU-145 human prostate cancer cell line, in vitro, Homo sapiens",
"canonical_assay_context=MTT cell viability/proliferation IC50",
"canonical_measurement_scal... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 0.897077 | 1.777717 | 0.88064 | 0.798862 | {
"nontransfer": 0.9991102487207547,
"transfer": 0.0008897512792452363
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT cell viability/proliferation IC50","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"MTT cell viability/proliferation IC... | 52.05 | 1.102368 | 0.00089 | 0.798862 | 0.00089 | 0.99911 | safety_canonical_v27 | 0 | true | 0.780822 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT cell viability/proliferation IC50","L3"] | WXDCPCOGKPVYIN-QNMIOERPSA-N | ZNGCDWOWEZBNJC-ALMBTRMVSA-N | O=C1OCC2C(NC(=S)Nc3ccccc3)c3cc4c(cc3C(c3ccccc3)C12)OCO4 | O=C1OCC2C(NC(=S)Nc3ccccc3)c3cc4c(cc3C(c3ccccc3)C12)OCO4 | {
"aggregation_method": "individual_record",
"display_measurement_text": "7.89",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 7.89,
"aggregate_max": 7.89,
"aggregate_q1": 7.89,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "59.94",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 59.94,
"aggregate_max": 59.94,
"aggregate_q1": 59.94,
"aggreg... | 523 | 499 | 384 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Cytotoxicity/viability endpoint.","assay_method":"MTT colorimetric assay, IC50 determination","biological_test_system":"DU-145 human prostate cancer cell line, in vitro, Homo sapiens","canonical_assay_context":"MTT cell viability/proliferation IC50","canonical_measurement_scale_id":"... | {"assay_interpretation_conditions":"Cytotoxicity/viability endpoint.","assay_method":"MTT colorimetric assay, IC50 determination","biological_test_system":"DU-145 human prostate cancer cell line, in vitro, Homo sapiens","canonical_assay_context":"MTT cell viability/proliferation IC50","canonical_measurement_scale_id":"... | L3 | gold_v1 | sr_c84797890d6e40f28fe659e174df924e | sr_561ec91cc3e94e4ab91d97daeeba7ba8 | ["carcinogens_v1","cell viability or survival","µM","__unknown__","MTT cell viability/proliferation IC50"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CCO</SMILES>
- Assay interpretation conditions: Proliferation inhibition was dose-dependent; the authors interpret the cytotoxic effect as dose-dependent, so the growth-inhibiti... | (A) | train | 980df010fcdf517e7024a0b92269effe4aed70b9b5c65673109219c33b4ed355 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:2fff75d1abeb4f201070fcbc76a35b37503cafd1837b6457112a15d410c7beef | carcinogens:27a1faac15667e54b6d19c16e7040a477f97dc2fcd7c36181442889bc9443aae | carcinogens:2fff75d1abeb4f201070fcbc76a35b37503cafd1837b6457112a15d410c7beef | carcinogens:27a1faac15667e54b6d19c16e7040a477f97dc2fcd7c36181442889bc9443aae | GRYLNZFGIOXLOG-UHFFFAOYSA-N | LFQSCWFLJHTTHZ-UHFFFAOYSA-N | O=[N+]([O-])O | CCO | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5mol/L","__unknown__","cell proliferation assay","L3"] | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5mol/L","__unknown__","cell proliferation assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Antiproliferative endpoint; maximum inhibition observed at 100 µmol/L",
"assay_method=Cellular proliferation inhibition (ID50) assay",
"biological_test_system=SK-N-MC human neuroblastoma cells, in vitro",
"canonical_assay_context=cell proliferation assay",
"canonical_measure... | [
"assay_interpretation_conditions=Proliferation inhibition was dose-dependent; the authors interpret the cytotoxic effect as dose-dependent, so the growth-inhibition endpoint is coupled to increasing concentrations of GA.",
"assay_method=In vitro cell proliferation inhibition assay with IC50 determination",
"bio... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 1.69897 | 1.517196 | 0.181774 | 0.843552 | {
"nontransfer": 0.13644524064280183,
"transfer": 0.8635547593571982
} | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5mol/L","__unknown__","cell proliferation assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"proliferation or DNA synthesis\",\"\\u00b5mol/L\",\"__unknown__\",\"cell proliferation assay\",... | 17.1 | 0.215487 | 0.863555 | 0.843552 | 0.863555 | 0.136445 | safety_canonical_v27 | 1 | true | 0.076923 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5mol/L","__unknown__","cell proliferation assay","L3"] | GRYLNZFGIOXLOG-UHFFFAOYSA-N | LFQSCWFLJHTTHZ-UHFFFAOYSA-N | parent:GRYLNZFGIOXLOG-UHFFFAOYSA-N | parent:LFQSCWFLJHTTHZ-UHFFFAOYSA-N | {
"aggregation_method": "individual_record",
"display_measurement_text": "50",
"display_unit_text": "µmol/L",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 50,
"aggregate_max": 50,
"aggregate_q1": 50,
"aggregate_q3":... | {
"aggregation_method": "individual_record",
"display_measurement_text": "32.9",
"display_unit_text": "µmol/L",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 32.9,
"aggregate_max": 32.9,
"aggregate_q1": 32.9,
"aggreg... | 26 | 25 | 18 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Antiproliferative endpoint; maximum inhibition observed at 100 \u00b5mol/L","assay_method":"Cellular proliferation inhibition (ID50) assay","biological_test_system":"SK-N-MC human neuroblastoma cells, in vitro","canonical_assay_context":"cell proliferation assay","canonical_measureme... | {"assay_interpretation_conditions":"Proliferation inhibition was dose-dependent; the authors interpret the cytotoxic effect as dose-dependent, so the growth-inhibition endpoint is coupled to increasing concentrations of GA.","assay_method":"In vitro cell proliferation inhibition assay with IC50 determination","biologic... | L3 | gold_v1 | sr_d534228d70aa4af699c44dcc06028c0e | sr_61b6fce25b5e419ab55b4b6f6912c5c5 | ["carcinogens_v1","proliferation or DNA synthesis","µmol/L","__unknown__","cell proliferation assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>C=C1C(=O)[C@]23[C@H](OC(=O)c4ccc(F)cc4)[C@H]1CC[C@H]2[C@@]12CO[C@]3(O)[C@@H](O)[C@@H]1C(C)(C)CC[C@@H]2O</SMILES>
- Assay interpretation conditions: CCK-8 assay; IC50 mean ± SEM ... | (A) | train | 58dfd85c96bc99687edfb607f4f1fb7a67293a3228125ad4be313c5b36c77303 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:5c82d94ca8e5102c4dfb87822f3d1007adeda029897f5bf3cdb7aae07f974e16 | carcinogens:f88a5c836b4394231224652c54ca556884156cc1edb2a65fe53290508cea6263 | carcinogens:5c82d94ca8e5102c4dfb87822f3d1007adeda029897f5bf3cdb7aae07f974e16 | carcinogens:f88a5c836b4394231224652c54ca556884156cc1edb2a65fe53290508cea6263 | RCINICONZNJXQF-MZXODVADSA-N | BJSCSLYCYKSNJF-ULLBHDERSA-N | CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O | C=C1C(=O)[C@]23[C@H](OC(=O)c4ccc(F)cc4)[C@H]1CC[C@H]2[C@@]12CO[C@]3(O)[C@@H](O)[C@@H]1C(C)(C)CC[C@@H]2O | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","CCK-8 cell viability assay","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","CCK-8 cell viability assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Viability decreased in a dose- and time-dependent manner relative to untreated control; CCK-8 readout used as a direct viability endpoint.",
"assay_method=CCK-8 cell viability/proliferation assay (colorimetric metabolic readout)",
"biological_test_system=MDA-MB-231 human breast ... | [
"assay_interpretation_conditions=CCK-8 assay; IC50 mean ± SEM from at least three independent experiments; Paclitaxel positive control. Reported as having potent inhibiting activity on HepG2 cell line.",
"assay_method=CCK-8 cell viability (cytotoxicity) assay",
"biological_test_system=in-vitro; human hepatic ca... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 0.643453 | 0.491362 | 0.152091 | 0.777387 | {
"nontransfer": 0.11470449816976291,
"transfer": 0.8852955018302371
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","CCK-8 cell viability assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"CCK-8 cell viability assay\",\"L3\"... | 1.3 | 0.195644 | 0.885296 | 0.777387 | 0.885296 | 0.114704 | safety_canonical_v27 | 1 | true | 0.231405 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","CCK-8 cell viability assay","L3"] | RCINICONZNJXQF-MZXODVADSA-N | BJSCSLYCYKSNJF-ULLBHDERSA-N | O=C(CC(NC(=O)c1ccccc1)c1ccccc1)OC1C=C2CC(=O)C3CCC4OCC4C3C(OC(=O)c3ccccc3)C(C2)C1 | C=C1C(=O)C23C4CC5CCCCC5(CO4)C2CCC1C3OC(=O)c1ccccc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "4.4",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 4.4,
"aggregate_max": 4.4,
"aggregate_q1": 4.4,
"aggregate_q3":... | {
"aggregation_method": "individual_record",
"display_measurement_text": "3.1",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 3.1,
"aggregate_max": 3.1,
"aggregate_q1": 3.1,
"aggregate_q3":... | 228 | 218 | 126 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Viability decreased in a dose- and time-dependent manner relative to untreated control; CCK-8 readout used as a direct viability endpoint.","assay_method":"CCK-8 cell viability/proliferation assay (colorimetric metabolic readout)","biological_test_system":"MDA-MB-231 human breast can... | {"assay_interpretation_conditions":"CCK-8 assay; IC50 mean \u00b1 SEM from at least three independent experiments; Paclitaxel positive control. Reported as having potent inhibiting activity on HepG2 cell line.","assay_method":"CCK-8 cell viability (cytotoxicity) assay","biological_test_system":"in-vitro; human hepatic ... | L3 | gold_v1 | sr_348d4b2dc0524251a6226fc9ebbbabfc | sr_451abf2ff3514315b45d8766c3cca941 | ["carcinogens_v1","cell viability or survival","µM","__unknown__","CCK-8 cell viability assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>COc1cc(-c2nc3cc(/C=C4\SC(=O)N(Cc5cc(OC)c(OC)c(OC)c5)C4=O)ccc3[nH]2)ccc1OCC(C)C</SMILES>
- Assay method: MTT reduction assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium... | (B) | train | 5846934e927acc6a870a25e7b3aa80da83fa1ee83547aa6a897fe7947114d91c | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:6ef8c5b4de5c0743c12bbb4fed46b1e8372d5e30e81958c020ca4c568a582b78 | carcinogens:2277cceaa3f72fbefa23cbaf9fae5461ade84e0ba078d2894861ef64a12b6a6d | carcinogens:6ef8c5b4de5c0743c12bbb4fed46b1e8372d5e30e81958c020ca4c568a582b78 | carcinogens:2277cceaa3f72fbefa23cbaf9fae5461ade84e0ba078d2894861ef64a12b6a6d | KADMPCJRANCNFW-ZDLGFXPLSA-N | NPHOTAUVQSGGOR-MUXKCCDJSA-N | COc1ccc2[nH]c(=O)c(/C=C3\SC(=O)N(CC(=O)Nc4ccc(Cl)cc4)C3=O)cc2c1 | COc1cc(-c2nc3cc(/C=C4\SC(=O)N(Cc5cc(OC)c(OC)c(OC)c5)C4=O)ccc3[nH]2)ccc1OCC(C)C | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Cytotoxicity (anti-proliferative) endpoint measured by MTT",
"assay_method=MTT reduction assay, sub-IC50 treatment concentration, reporting IC50 for anti-proliferative/cytotoxic activity",
"biological_test_system=In-vitro; Caco-2 cell line (colorectal cancer), human; cancer cell... | [
"assay_method=MTT reduction assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction)",
"biological_test_system=In vitro; HeLa human cervical cancer cell line; Homo sapiens",
"canonical_assay_context=MTT assay (IC50)",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 1.916454 | -0.60206 | 2.518514 | 0.864106 | {
"nontransfer": 0.9999999999879972,
"transfer": 1.2002852380315056e-11
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"MTT assay (IC50)\",\"L3\"]",
"q... | 82.25 | 2.914588 | 0 | 0.864106 | 0 | 1 | safety_canonical_v27 | 0 | true | 0.30303 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","MTT assay (IC50)","L3"] | KADMPCJRANCNFW-ZDLGFXPLSA-N | NPHOTAUVQSGGOR-MUXKCCDJSA-N | O=C(CN1C(=O)SC(=Cc2cc3ccccc3[nH]c2=O)C1=O)Nc1ccccc1 | O=C1SC(=Cc2ccc3[nH]c(-c4ccccc4)nc3c2)C(=O)N1Cc1ccccc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "82.5",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 82.5,
"aggregate_max": 82.5,
"aggregate_q1": 82.5,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.25",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.25,
"aggregate_max": 0.25,
"aggregate_q1": 0.25,
"aggregate_... | 1,392 | 1,368 | 880 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Cytotoxicity (anti-proliferative) endpoint measured by MTT","assay_method":"MTT reduction assay, sub-IC50 treatment concentration, reporting IC50 for anti-proliferative/cytotoxic activity","biological_test_system":"In-vitro; Caco-2 cell line (colorectal cancer), human; cancer cell li... | {"assay_interpretation_conditions":null,"assay_method":"MTT reduction assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction)","biological_test_system":"In vitro; HeLa human cervical cancer cell line; Homo sapiens","canonical_assay_context":"MTT assay (IC50)","canonical_measurement_scale_id":"__u... | L3 | gold_v1 | sr_41b8cf2e11e34e3a96660838957a29df | sr_421361902326451d9be3e62ef18a1c78 | ["carcinogens_v1","cell viability or survival","µM","__unknown__","MTT assay (IC50)"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CC(=O)c1sc(NN=C2c3ccccc3-c3nc4ccccc4nc32)nc1C</SMILES>
- Assay interpretation conditions: Remarkable activity against HepG-2; also 12.26 ± 0.94 (HCT-116) and 14 ± 1.03 (MCF-7).
... | (B) | train | b138da5420cd9256dea2f84be622f4a1b8269a3a05111bd846974af713244624 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:aab8723fa5419cc731cae8b4721951cd86be3a0041bff061764cc72fbdf58e19 | carcinogens:011d12dcf8f1782b116aed3c1acaf921b727e8415eccbd9b0f4f9f457bf3e0fe | carcinogens:aab8723fa5419cc731cae8b4721951cd86be3a0041bff061764cc72fbdf58e19 | carcinogens:011d12dcf8f1782b116aed3c1acaf921b727e8415eccbd9b0f4f9f457bf3e0fe | CTFVFFMLSUYFIP-BGABXYSRSA-N | XQLQEVCRTHVBLY-UHFFFAOYSA-N | CN(C)CCCNC(=O)c1cccc2nc3c(nc12)-c1ccccc1/C3=N\OCCCN(C)C | CC(=O)c1sc(NN=C2c3ccccc3-c3nc4ccccc4nc32)nc1C | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","cell viability/growth inhibition assay (IC50)","L3"] | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","cell viability/growth inhibition assay (IC50)","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=antiproliferative activity (cell growth IC50 determination)",
"biological_test_system=in-vitro human hepatocellular carcinoma cell line Huh-7 (liver carcinoma)",
"canonical_assay_context=cell viability/growth inhibition assay (IC50)",
"canonical_measurement_scale_id=__unknown__",
"endpoint_mea... | [
"assay_interpretation_conditions=Remarkable activity against HepG-2; also 12.26 ± 0.94 (HCT-116) and 14 ± 1.03 (MCF-7).",
"assay_method=in vitro cytotoxic/antiproliferative IC50 assay",
"biological_test_system=human hepatic cancer cell line HepG-2, in vitro",
"canonical_assay_context=cell viability/growth inh... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | -0.19382 | 0.994317 | 1.188137 | 0.714881 | {
"nontransfer": 0.9999966949852379,
"transfer": 0.000003305014762144103
} | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","cell viability/growth inhibition assay (IC50)","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"proliferation or DNA synthesis\",\"\\u00b5M\",\"__unknown__\",\"cell viability/growth inhibitio... | 9.23 | 1.662007 | 0.000003 | 0.714881 | 0.000003 | 0.999997 | safety_canonical_v27 | 0 | true | 0.315789 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","cell viability/growth inhibition assay (IC50)","L3"] | CTFVFFMLSUYFIP-BGABXYSRSA-N | XQLQEVCRTHVBLY-UHFFFAOYSA-N | N=C1c2ccccc2-c2nc3ccccc3nc21 | c1ccc2c(c1)C(=NNc1nccs1)c1nc3ccccc3nc1-2 | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.64",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.64,
"aggregate_max": 0.64,
"aggregate_q1": 0.64,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "9.87",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 9.87,
"aggregate_max": 9.87,
"aggregate_q1": 9.87,
"aggregate_... | 57 | 57 | 51 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":null,"assay_method":"antiproliferative activity (cell growth IC50 determination)","biological_test_system":"in-vitro human hepatocellular carcinoma cell line Huh-7 (liver carcinoma)","canonical_assay_context":"cell viability/growth inhibition assay (IC50)","canonical_measurement_scale... | {"assay_interpretation_conditions":"Remarkable activity against HepG-2; also 12.26 \u00b1 0.94 (HCT-116) and 14 \u00b1 1.03 (MCF-7).","assay_method":"in vitro cytotoxic/antiproliferative IC50 assay","biological_test_system":"human hepatic cancer cell line HepG-2, in vitro","canonical_assay_context":"cell viability/grow... | L3 | gold_v1 | sr_c9e77cb2f4a44ef4929485bd88f0128d | sr_6bc645dfdbf7480d910f52287794cf61 | ["carcinogens_v1","proliferation or DNA synthesis","µM","__unknown__","cell viability/growth inhibition assay (IC50)"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>COc1cc(OC)cc(C(=O)N[C@@H](CSCCCC(=O)NO)C(=O)NCc2ccccc2)c1</SMILES>
- Assay interpretation conditions: Clonogenic survival/cytotoxicity; selectivity (IC50 NFF/MM96L) = 2.6.
- Ass... | (A) | train | 13f1d2ddf029d8757ae692df403b31e46a7a305e32314e710949cf6bee6f3ca8 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:3c178b7dc23a479f265c352062d56b37e6afd5ec95107c9057bbaf42f51e8d76 | carcinogens:74d55176c92e83df8fb33a0463543112f2e0771f6e67a3dbcde22e5713252c38 | carcinogens:3c178b7dc23a479f265c352062d56b37e6afd5ec95107c9057bbaf42f51e8d76 | carcinogens:74d55176c92e83df8fb33a0463543112f2e0771f6e67a3dbcde22e5713252c38 | QGZKDVFQNNGYKY-UHFFFAOYSA-N | XPJWQNMMYQJMNW-FQEVSTJZSA-N | N | COc1cc(OC)cc(C(=O)N[C@@H](CSCCCC(=O)NO)C(=O)NCc2ccccc2)c1 | ["carcinogens_v1","clonogenic survival","\u00b5M","__unknown__","clonogenic survival assay","L3"] | ["carcinogens_v1","clonogenic survival","\u00b5M","__unknown__","clonogenic survival assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Fancc− mutant cells exhibit acute sensitivity to cisplatin; confirmed to reproduce previously reported sensitivity. BRCA1 loss abrogates the toxic effect at 2.5 µM where only 5-10% of Fancc− cells survive.",
"assay_method=Clonogenic survival assay with increasing concentrations of... | [
"assay_interpretation_conditions=Clonogenic survival/cytotoxicity; selectivity (IC50 NFF/MM96L) = 2.6.",
"assay_method=Clonogenic survival assay with SRB staining and cell count",
"biological_test_system=MM96L human melanoma cells (in vitro)",
"canonical_assay_context=clonogenic survival assay",
"canonical_... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | -0.09691 | 0.230449 | 0.327359 | 0.868813 | {
"nontransfer": 0.44223137383218836,
"transfer": 0.5577686261678116
} | ["carcinogens_v1","clonogenic survival","\u00b5M","__unknown__","clonogenic survival assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"clonogenic survival\",\"\\u00b5M\",\"__unknown__\",\"clonogenic survival assay\",\"L3\"]",
... | 0.9 | 0.376789 | 0.557769 | 0.868813 | 0.557769 | 0.442231 | safety_canonical_v27 | 1 | false | 0 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","clonogenic survival","\u00b5M","__unknown__","clonogenic survival assay","L3"] | QGZKDVFQNNGYKY-UHFFFAOYSA-N | XPJWQNMMYQJMNW-FQEVSTJZSA-N | parent:QGZKDVFQNNGYKY-UHFFFAOYSA-N | O=C(CNC(=O)c1ccccc1)NCc1ccccc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.8",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.8,
"aggregate_max": 0.8,
"aggregate_q1": 0.8,
"aggregate_q3":... | {
"aggregation_method": "individual_record",
"display_measurement_text": "1.7",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 1.7,
"aggregate_max": 1.7,
"aggregate_q1": 1.7,
"aggregate_q3":... | 94 | 90 | 71 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Fancc\u2212 mutant cells exhibit acute sensitivity to cisplatin; confirmed to reproduce previously reported sensitivity. BRCA1 loss abrogates the toxic effect at 2.5 \u00b5M where only 5-10% of Fancc\u2212 cells survive.","assay_method":"Clonogenic survival assay with increasing conc... | {"assay_interpretation_conditions":"Clonogenic survival/cytotoxicity; selectivity (IC50 NFF/MM96L) = 2.6.","assay_method":"Clonogenic survival assay with SRB staining and cell count","biological_test_system":"MM96L human melanoma cells (in vitro)","canonical_assay_context":"clonogenic survival assay","canonical_measure... | L3 | gold_v1 | sr_8a184acca26d49e2b6fe7412ca30a44b | sr_7c7bc2b9d77b45c3a4700593adb70a7f | ["carcinogens_v1","clonogenic survival","µM","__unknown__","clonogenic survival assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=O)=NC(=O)CCCCCCCC(=O)NCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)c2)n1</SMILES>
- Assay interpretation conditions: Growth-inhibition readout; dat... | (B) | train | 44d69d94b17882bddf2952e930122ddd6a03064b31a21e82ee75e5ea88e0665d | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:1b38ab2f45435491f49195613491f1a485709b7ce7ae0e424915cc1946b13380 | carcinogens:ab2d47ba94fe6503ff4dbe0487f0a4e97d081632fee18b99a7bb1910d3530f66 | carcinogens:1b38ab2f45435491f49195613491f1a485709b7ce7ae0e424915cc1946b13380 | carcinogens:ab2d47ba94fe6503ff4dbe0487f0a4e97d081632fee18b99a7bb1910d3530f66 | NXPQSFVKBBHKOK-UHFFFAOYSA-N | SRVYTIFEXUTLAJ-UHFFFAOYSA-N | COc1ccccc1N1C(=O)CSC1c1cccc(C(=O)NCCc2ccc(Br)cc2)c1 | COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=O)=NC(=O)CCCCCCCC(=O)NCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)c2)n1 | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M (IC50)","__unknown__","Antiproliferative IC50","L3"] | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M (IC50)","__unknown__","Antiproliferative IC50","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=anti-proliferation activity assay (IC50 determination)",
"biological_test_system=A549 human lung carcinoma cell line, in vitro, Homo sapiens",
"canonical_assay_context=Antiproliferative IC50",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=inhibition of cell proliferation (hal... | [
"assay_interpretation_conditions=Growth-inhibition readout; data are the average of three independent experiments; concurrent cytotoxicity not separately scored here",
"assay_method=Anti-proliferation activity assay (IC50 determination, 72 h exposure)",
"biological_test_system=in-vitro; A549 human lung carcinom... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | -0.677781 | 0.08636 | 0.764141 | 0.827634 | {
"nontransfer": 0.9946899415174658,
"transfer": 0.005310058482534137
} | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M (IC50)","__unknown__","Antiproliferative IC50","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"proliferation or DNA synthesis\",\"\\u00b5M (IC50)\",\"__unknown__\",\"Antiproliferative IC50\"... | 1.01 | 0.923283 | 0.00531 | 0.827634 | 0.00531 | 0.99469 | safety_canonical_v27 | 0 | true | 0.236641 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M (IC50)","__unknown__","Antiproliferative IC50","L3"] | NXPQSFVKBBHKOK-UHFFFAOYSA-N | SRVYTIFEXUTLAJ-UHFFFAOYSA-N | O=C(NCCc1ccccc1)c1cccc(C2SCC(=O)N2c2ccccc2)c1 | O=C(CCCCCCCC(=O)NCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)N=[SH](=O)Cc1cccc(Nc2ncnc(-c3ccccc3)n2)c1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.21",
"display_unit_text": "µM (IC50)",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.21,
"aggregate_max": 0.21,
"aggregate_q1": 0.21,
"agg... | {
"aggregation_method": "individual_record",
"display_measurement_text": "1.22",
"display_unit_text": "µM (IC50)",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 1.22,
"aggregate_max": 1.22,
"aggregate_q1": 1.22,
"agg... | 30 | 30 | 25 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":null,"assay_method":"anti-proliferation activity assay (IC50 determination)","biological_test_system":"A549 human lung carcinoma cell line, in vitro, Homo sapiens","canonical_assay_context":"Antiproliferative IC50","canonical_measurement_scale_id":"__unknown__","confidence":0.95,"effe... | {"assay_interpretation_conditions":"Growth-inhibition readout; data are the average of three independent experiments; concurrent cytotoxicity not separately scored here","assay_method":"Anti-proliferation activity assay (IC50 determination, 72 h exposure)","biological_test_system":"in-vitro; A549 human lung carcinoma c... | L3 | gold_v1 | sr_1e9aedfff0f34cb9899a014f85630114 | sr_75fa2d1c41b642bdbabcff6328d5fc93 | ["carcinogens_v1","proliferation or DNA synthesis","µM (IC50)","__unknown__","Antiproliferative IC50"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CC(C)c1ccc(NC(=O)Nc2ccc(NC(=O)c3c[nH]c4ccc(Cl)cc4c3=O)cc2)cc1</SMILES>
- Assay interpretation conditions: Selectivity index (SI) = CC50(THLE-2)/IC50(HepG2 cancer cell line) = 13... | (A) | train | 90f968c89da736e11fac30b22e0534fd9f3c881ed1c7cd70179e30ddc4a8d02b | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:3a05f12b74b2dd0b5fd065cdb106a3fe9b574d4a24255a02ac956727f24f592f | carcinogens:af1c890fd5ef2ed50c1ef8e891fe0a06fa31c3160dbcf4bb8ef957bcc0f482bd | carcinogens:3a05f12b74b2dd0b5fd065cdb106a3fe9b574d4a24255a02ac956727f24f592f | carcinogens:af1c890fd5ef2ed50c1ef8e891fe0a06fa31c3160dbcf4bb8ef957bcc0f482bd | NNCXKCOKEODHIY-UHFFFAOYSA-N | BJYWOUFEABIITB-UHFFFAOYSA-N | O=C(Nc1ccc(NC(=O)c2c[nH]c3ccc(F)cc3c2=O)cc1)Nc1cccc(C(F)(F)F)c1 | CC(C)c1ccc(NC(=O)Nc2ccc(NC(=O)c3c[nH]c4ccc(Cl)cc4c3=O)cc2)cc1 | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","cytotoxicity assay (CC50)","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","cytotoxicity assay (CC50)","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Selectivity index (SI) = CC50(THLE-2)/IC50(HepG2 cancer cell line) = 5.52, higher than reference drug sorafenib (SI = 2.20).",
"assay_method=Cytotoxicity screening against normal liver cell line, CC50 determination",
"biological_test_system=THLE-2 (Transformed Human Liver Epithe... | [
"assay_interpretation_conditions=Selectivity index (SI) = CC50(THLE-2)/IC50(HepG2 cancer cell line) = 13.13, higher than reference drug sorafenib (SI = 2.20).",
"assay_method=Cytotoxicity screening against normal liver cell line, CC50 determination",
"biological_test_system=THLE-2 (Transformed Human Liver Epith... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 1.181272 | 1.322219 | 0.140948 | 0.839697 | {
"nontransfer": 0.08936214230668138,
"transfer": 0.9106378576933186
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","cytotoxicity assay (CC50)","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"cytotoxicity assay (CC50)\",\"L3\"]... | 5.82 | 0.167855 | 0.910638 | 0.839697 | 0.910638 | 0.089362 | safety_canonical_v27 | 1 | true | 0.515625 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","cytotoxicity assay (CC50)","L3"] | NNCXKCOKEODHIY-UHFFFAOYSA-N | BJYWOUFEABIITB-UHFFFAOYSA-N | O=C(Nc1ccccc1)Nc1ccc(NC(=O)c2c[nH]c3ccccc3c2=O)cc1 | O=C(Nc1ccccc1)Nc1ccc(NC(=O)c2c[nH]c3ccccc3c2=O)cc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "15.18",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 15.18,
"aggregate_max": 15.18,
"aggregate_q1": 15.18,
"aggreg... | {
"aggregation_method": "individual_record",
"display_measurement_text": "21",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 21,
"aggregate_max": 21,
"aggregate_q1": 21,
"aggregate_q3": 21
... | 58 | 57 | 41 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Selectivity index (SI) = CC50(THLE-2)/IC50(HepG2 cancer cell line) = 5.52, higher than reference drug sorafenib (SI = 2.20).","assay_method":"Cytotoxicity screening against normal liver cell line, CC50 determination","biological_test_system":"THLE-2 (Transformed Human Liver Epithelia... | {"assay_interpretation_conditions":"Selectivity index (SI) = CC50(THLE-2)/IC50(HepG2 cancer cell line) = 13.13, higher than reference drug sorafenib (SI = 2.20).","assay_method":"Cytotoxicity screening against normal liver cell line, CC50 determination","biological_test_system":"THLE-2 (Transformed Human Liver Epitheli... | L3 | gold_v1 | sr_7d2bacf5db2b41d2abec9c7296e79d92 | sr_31fb029298714aa0acc307f059be6580 | ["carcinogens_v1","cell viability or survival","µM","__unknown__","cytotoxicity assay (CC50)"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CC(=C/C=C/C(C)=C/C(=O)O)/C=C1\CCCc2ccccc21</SMILES>
- Assay interpretation conditions: Survival read after 48 h treatment. alamarBlue used as a direct survival endpoint.
- Assay... | (A) | train | 167c7bc92075b14ab4cc9e632086a9e018a6186531f637b8deee13e2f262a62c | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:9c2e8da27d3798a9af2e4080e247746e2b1d8e262b291a50ce01c4a8aab57fc3 | carcinogens:797d7202ea266da79e6504e1b49183a9564c8f210e33cd6d5cf5ab9d33493dc7 | carcinogens:9c2e8da27d3798a9af2e4080e247746e2b1d8e262b291a50ce01c4a8aab57fc3 | carcinogens:797d7202ea266da79e6504e1b49183a9564c8f210e33cd6d5cf5ab9d33493dc7 | SHGAZHPCJJPHSC-YCNIQYBTSA-N | PPGNMFUMZSAZCW-VOYUZAMQSA-N | CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1 | CC(=C/C=C/C(C)=C/C(=O)O)/C=C1\CCCc2ccccc21 | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction cell viability assay","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction cell viability assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Decreased viability used as a direct survival/cytotoxicity endpoint.",
"assay_method=alamarBlue cell viability assay",
"biological_test_system=D341 human medulloblastoma (MB) PDX cell line, in vitro",
"canonical_assay_context=resazurin reduction cell viability assay",
"canon... | [
"assay_interpretation_conditions=Survival read after 48 h treatment. alamarBlue used as a direct survival endpoint.",
"assay_method=alamarBlue® metabolic survival assay, survival reported as mean fold change ± SEM",
"biological_test_system=SJCRH30 RMS cell line (Homo sapiens), adherent monolayer culture",
"ca... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 1.477121 | 1.416641 | 0.060481 | 0.881533 | {
"nontransfer": 0.03509692395227082,
"transfer": 0.9649030760477292
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction cell viability assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"resazurin reduction cell viability ... | 3.9 | 0.068609 | 0.964903 | 0.881533 | 0.964903 | 0.035097 | safety_canonical_v27 | 1 | true | 0.403509 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction cell viability assay","L3"] | SHGAZHPCJJPHSC-YCNIQYBTSA-N | PPGNMFUMZSAZCW-VOYUZAMQSA-N | C1=CCCCC1 | C=C1CCCc2ccccc21 | {
"aggregation_method": "individual_record",
"display_measurement_text": "30",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 30,
"aggregate_max": 30,
"aggregate_q1": 30,
"aggregate_q3": 30
... | {
"aggregation_method": "individual_record",
"display_measurement_text": "26.1",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 26.1,
"aggregate_max": 26.1,
"aggregate_q1": 26.1,
"aggregate_... | 39 | 35 | 26 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":"Decreased viability used as a direct survival/cytotoxicity endpoint.","assay_method":"alamarBlue cell viability assay","biological_test_system":"D341 human medulloblastoma (MB) PDX cell line, in vitro","canonical_assay_context":"resazurin reduction cell viability assay","canonical_me... | {"assay_interpretation_conditions":"Survival read after 48 h treatment. alamarBlue used as a direct survival endpoint.","assay_method":"alamarBlue\u00ae metabolic survival assay, survival reported as mean fold change \u00b1 SEM","biological_test_system":"SJCRH30 RMS cell line (Homo sapiens), adherent monolayer culture"... | L3 | gold_v1 | sr_afb3ea939cfc4338b4eb009edaa42cd3 | sr_3bce62b3726a4e30b3a985c58dd6436d | ["carcinogens_v1","cell viability or survival","µM","__unknown__","resazurin reduction cell viability assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>COc1ncc(-c2ccc3ncc(C(=O)NCCN4CCOCC4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F</SMILES>
- Assay interpretation conditions: CCK-8 proliferation-inhibitory endpoint measured after 72 h treatm... | (A) | train | f5ff811d026435f334105f3d633f5c5d1e343dc6708d4f51b9f8532523bccacb | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:f14a963e666002dd78f77db3d520fe1b977caa424d8060a2b6a54459a77c6eaf | carcinogens:8aed2fc29d4673393edea3154ce6c835c5e9439fa5b950f658246fc2091ed988 | carcinogens:f14a963e666002dd78f77db3d520fe1b977caa424d8060a2b6a54459a77c6eaf | carcinogens:8aed2fc29d4673393edea3154ce6c835c5e9439fa5b950f658246fc2091ed988 | PZBCKZWLPGJMAO-UHFFFAOYSA-N | AOFNYCXYCYLTJD-UHFFFAOYSA-N | COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21 | COc1ncc(-c2ccc3ncc(C(=O)NCCN4CCOCC4)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","CCK-8 cell viability/proliferation assay","L3"] | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","CCK-8 cell viability/proliferation assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=CCK-8 proliferation assay",
"biological_test_system=HCT116 human colorectal carcinoma cell line (PIK3CA mutant), in vitro",
"canonical_assay_context=CCK-8 cell viability/proliferation assay",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50 of proliferation inhibition",
"... | [
"assay_interpretation_conditions=CCK-8 proliferation-inhibitory endpoint measured after 72 h treatment; IC50 by 8-dose response in triplicate.",
"assay_method=CCK-8 assay",
"biological_test_system=HCT116 human colorectal carcinoma cells, in vitro",
"canonical_assay_context=CCK-8 cell viability/proliferation a... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 0.12 | 0.34 | 0.22 | 39.104833 | {
"nontransfer": 0.019007317382776723,
"transfer": 0.9809926826172233
} | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","CCK-8 cell viability/proliferation assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"proliferation or DNA synthesis\",\"\\u00b5M\",\"__unknown__\",\"CCK-8 cell viability/proliferat... | 0.22 | 0.005626 | 0.980993 | 39.104833 | 0.980993 | 0.019007 | safety_canonical_v27 | 1 | true | 0.25 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","proliferation or DNA synthesis","\u00b5M","__unknown__","CCK-8 cell viability/proliferation assay","L3"] | PZBCKZWLPGJMAO-UHFFFAOYSA-N | AOFNYCXYCYLTJD-UHFFFAOYSA-N | O=C(NC1=Nc2cc(OCCCN3CCOCC3)ccc2C2=NCCN12)c1cncnc1 | O=C(NCCN1CCOCC1)c1cnc2ccc(-c3cncc(NS(=O)(=O)c4ccccc4)c3)cn12 | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.12",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.12,
"aggregate_max": 0.12,
"aggregate_q1": 0.12,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.34",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.34,
"aggregate_max": 0.34,
"aggregate_q1": 0.34,
"aggregate_... | 131 | 129 | 81 | id | train_exact_bucket.v27_safety | identity | {"assay_interpretation_conditions":null,"assay_method":"CCK-8 proliferation assay","biological_test_system":"HCT116 human colorectal carcinoma cell line (PIK3CA mutant), in vitro","canonical_assay_context":"CCK-8 cell viability/proliferation assay","canonical_measurement_scale_id":"__unknown__","confidence":0.9,"effect... | {"assay_interpretation_conditions":"CCK-8 proliferation-inhibitory endpoint measured after 72 h treatment; IC50 by 8-dose response in triplicate.","assay_method":"CCK-8 assay","biological_test_system":"HCT116 human colorectal carcinoma cells, in vitro","canonical_assay_context":"CCK-8 cell viability/proliferation assay... | L3 | gold_v1 | sr_88f70503555b405ba521393d60bb5ea4 | sr_f36abe2fbbea4169880ed5f153536c5b | ["carcinogens_v1","proliferation or DNA synthesis","µM","__unknown__","CCK-8 cell viability/proliferation assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CC(C)[C@@](O)(C(=O)OCC1=CCN2CC[C@@H](O)[C@@H]12)[C@H](C)O</SMILES>
- Assay interpretation conditions: Cytotoxicity endpoint; no exogenous metabolic-activation system reported.
-... | (B) | train | 49aa7bb89845cfac34fe8afda4a36b68e81d96d71b8a6eb4fa6ac9f87c04b8d9 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:1a24266cc1abb5c5cd3175a3308af862b9e157def5f264607d80bef23c24c86b | carcinogens:6e46722cf9b785a3d5392d4286a3f2df0f17ebb2ee6945df9957ad9838bb44ac | carcinogens:1a24266cc1abb5c5cd3175a3308af862b9e157def5f264607d80bef23c24c86b | carcinogens:6e46722cf9b785a3d5392d4286a3f2df0f17ebb2ee6945df9957ad9838bb44ac | WVTKBKWTSCPRNU-KYJUHHDHSA-N | SFVVQRJOGUKCEG-ZGFBFQLVSA-N | COc1ccc2cc1Oc1ccc(cc1)C[C@H]1c3cc(c(OC)cc3CCN1C)Oc1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3 | CC(C)[C@@](O)(C(=O)OCC1=CCN2CC[C@@H](O)[C@@H]12)[C@H](C)O | ["carcinogens_v1","cell viability or survival","\u00b5M (IC50)","__unknown__","CCK-8 cell viability assay","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M (IC50)","__unknown__","CCK-8 cell viability assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=GSLCs in stem-cell culture conditions (neurobasal/B27/bFGF/EGF); no exogenous metabolic activation stated",
"assay_method=CCK-8 assay",
"biological_test_system=U87 glioblastoma stem-like cells (GSLCs) in suspension/neurosphere culture, human, in vitro, cultured in neurobasal med... | [
"assay_interpretation_conditions=Cytotoxicity endpoint; no exogenous metabolic-activation system reported.",
"assay_method=CCK-8 cell-counting kit assay; cell survival readout",
"biological_test_system=In-vitro HepD hepatocyte cell line; baseline normal hepatocyte line",
"canonical_assay_context=CCK-8 cell vi... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 30.41 | 164.06 | 133.65 | 58.567923 | {
"nontransfer": 0.9999999932899437,
"transfer": 6.710056307055544e-9
} | ["carcinogens_v1","cell viability or survival","\u00b5M (IC50)","__unknown__","CCK-8 cell viability assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M (IC50)\",\"__unknown__\",\"CCK-8 cell viability assay\"... | 133.65 | 2.281966 | 0 | 58.567923 | 0 | 1 | safety_canonical_v27 | 0 | true | 0.108696 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M (IC50)","__unknown__","CCK-8 cell viability assay","L3"] | WVTKBKWTSCPRNU-KYJUHHDHSA-N | SFVVQRJOGUKCEG-ZGFBFQLVSA-N | c1cc2cc(c1)Oc1ccc(cc1)CC1NCCc3ccc(cc31)Oc1cccc3c1C(C2)NCC3 | C1=CC2CCCN2C1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "30.41",
"display_unit_text": "µM (IC50)",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 30.41,
"aggregate_max": 30.41,
"aggregate_q1": 30.41,
... | {
"aggregation_method": "individual_record",
"display_measurement_text": "164.06",
"display_unit_text": "µM (IC50)",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 164.06,
"aggregate_max": 164.06,
"aggregate_q1": 164.06... | 33 | 32 | 18 | id | train_exact_bucket.v27_safety | identity | {"assay_interpretation_conditions":"GSLCs in stem-cell culture conditions (neurobasal/B27/bFGF/EGF); no exogenous metabolic activation stated","assay_method":"CCK-8 assay","biological_test_system":"U87 glioblastoma stem-like cells (GSLCs) in suspension/neurosphere culture, human, in vitro, cultured in neurobasal medium... | {"assay_interpretation_conditions":"Cytotoxicity endpoint; no exogenous metabolic-activation system reported.","assay_method":"CCK-8 cell-counting kit assay; cell survival readout","biological_test_system":"In-vitro HepD hepatocyte cell line; baseline normal hepatocyte line","canonical_assay_context":"CCK-8 cell viabil... | L3 | gold_v1 | sr_e74d36d8011f42d69a34199b4ee58874 | sr_1c1852a2fe044661a966d03b72d360ee | ["carcinogens_v1","cell viability or survival","µM (IC50)","__unknown__","CCK-8 cell viability assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>O=C(O)c1ccccc1</SMILES>
- Assay method: Neutral red (NR) cytotoxicity assay
- Biological test system: RHEK-1 human keratinocyte cell line, in vitro, Homo sapiens
- Canonical ass... | (B) | train | ad7e2657424fab2145864fc4f83d5b8e9d4ebb08e2cf1c4f5d8d6f509e4f47f6 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:66fc830eb898d493d0a889188da0dbb23711408f112b3abe66f427e5fe30814b | carcinogens:7d7f0a8f919105a64fb6db818b7b17b8fff37b93a2599d178eea0f97c02aa74c | carcinogens:66fc830eb898d493d0a889188da0dbb23711408f112b3abe66f427e5fe30814b | carcinogens:7d7f0a8f919105a64fb6db818b7b17b8fff37b93a2599d178eea0f97c02aa74c | FRASJONUBLZVQX-UHFFFAOYSA-N | WPYMKLBDIGXBTP-UHFFFAOYSA-N | O=C1C=CC(=O)c2ccccc21 | O=C(O)c1ccccc1 | ["carcinogens_v1","cell viability or survival","mM","__unknown__","Neutral red uptake (NRU) cell viability/cytotoxicity assay","L3"] | ["carcinogens_v1","cell viability or survival","mM","__unknown__","Neutral red uptake (NRU) cell viability/cytotoxicity assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Viability determined by neutral red assay; NR50 is the midpoint cytotoxicity value. No exogenous metabolic-activation system reported.",
"assay_method=Neutral red (NR) viability assay; NR50 midpoint cytotoxicity value",
"biological_test_system=BALB/c mouse 3T3 fibroblast continu... | [
"assay_method=Neutral red (NR) cytotoxicity assay",
"biological_test_system=RHEK-1 human keratinocyte cell line, in vitro, Homo sapiens",
"canonical_assay_context=Neutral red uptake (NRU) cell viability/cytotoxicity assay",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=24-h midpoint NR50 t... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 0.01 | 29.5 | 29.49 | 8.236984 | {
"nontransfer": 0.9999999999999846,
"transfer": 1.543808066102485e-14
} | ["carcinogens_v1","cell viability or survival","mM","__unknown__","Neutral red uptake (NRU) cell viability/cytotoxicity assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"mM\",\"__unknown__\",\"Neutral red uptake (NRU) cell viability/c... | 29.49 | 3.580194 | 0 | 8.236984 | 0 | 1 | safety_canonical_v27 | 0 | true | 0.272727 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","mM","__unknown__","Neutral red uptake (NRU) cell viability/cytotoxicity assay","L3"] | FRASJONUBLZVQX-UHFFFAOYSA-N | WPYMKLBDIGXBTP-UHFFFAOYSA-N | O=C1C=CC(=O)c2ccccc21 | c1ccccc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "0.01",
"display_unit_text": "mM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 0.01,
"aggregate_max": 0.01,
"aggregate_q1": 0.01,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "29.5",
"display_unit_text": "mM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 29.5,
"aggregate_max": 29.5,
"aggregate_q1": 29.5,
"aggregate_... | 45 | 40 | 16 | id | train_exact_bucket.v27_safety | identity | {"assay_interpretation_conditions":"Viability determined by neutral red assay; NR50 is the midpoint cytotoxicity value. No exogenous metabolic-activation system reported.","assay_method":"Neutral red (NR) viability assay; NR50 midpoint cytotoxicity value","biological_test_system":"BALB/c mouse 3T3 fibroblast continuous... | {"assay_interpretation_conditions":null,"assay_method":"Neutral red (NR) cytotoxicity assay","biological_test_system":"RHEK-1 human keratinocyte cell line, in vitro, Homo sapiens","canonical_assay_context":"Neutral red uptake (NRU) cell viability/cytotoxicity assay","canonical_measurement_scale_id":"__unknown__","confi... | L3 | gold_v1 | sr_dd9ec90145ee4fa4b7ece649c322cad0 | sr_6c6f992206cf45a2933163f08b31e9d0 | ["carcinogens_v1","cell viability or survival","mM","__unknown__","Neutral red uptake (NRU) cell viability/cytotoxicity assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>CC(C)=CC[C@@H]1C[C@]23C[C@@H](CC=C(C)C)C(C)(C)[C@](CC=C(C)C)(C(=O)C(C(=O)c4ccc(O)c(O)c4)=C2OC1(C)C)C3=O</SMILES>
- Assay interpretation conditions: Doxorubicin positive control.... | (A) | train | 2f880f31ff313cb1023b49d5de9fc3234c81e22c39aa11114033c9f589c9b6a2 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:369b126472f51d90008fae01d3dbbeb0acb29f90dc79688f34403b9fdcbc96fe | carcinogens:c2e796ccb4c9a3c66b7d5d4aeed839e04f35c33467db81a9008af21682b9b19f | carcinogens:369b126472f51d90008fae01d3dbbeb0acb29f90dc79688f34403b9fdcbc96fe | carcinogens:c2e796ccb4c9a3c66b7d5d4aeed839e04f35c33467db81a9008af21682b9b19f | LUSHRJRLUBDDTB-KNQGVANASA-N | KXTNVBQRLRYVCO-OGHRFRAUSA-N | CC1(C)OC(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@H](C5=CC(O)OC5=O)OC(=O)[C@H]5O[C@]54[C@]3(C)C(=O)C[C@@H]12 | CC(C)=CC[C@@H]1C[C@]23C[C@@H](CC=C(C)C)C(C)(C)[C@](CC=C(C)C)(C(=O)C(C(=O)c4ccc(O)c(O)c4)=C2OC1(C)C)C3=O | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction viability/cytotoxicity IC50 assay","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction viability/cytotoxicity IC50 assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=resazurin reduction assay (RRA)",
"biological_test_system=CCRF-CEM human leukemia cell line, in vitro",
"canonical_assay_context=resazurin reduction viability/cytotoxicity IC50 assay",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50 for cytotoxicity (cell viability)",
"e... | [
"assay_interpretation_conditions=Doxorubicin positive control.",
"assay_method=resazurin cytotoxicity assay (IC50)",
"biological_test_system=CCRF-CEM human T-lymphoblast leukemia cell line, in vitro",
"canonical_assay_context=resazurin reduction viability/cytotoxicity IC50 assay",
"canonical_measurement_sca... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 0.761176 | 0.980003 | 0.218828 | 0.810883 | {
"nontransfer": 0.2139351458798684,
"transfer": 0.7860648541201316
} | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction viability/cytotoxicity IC50 assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5M\",\"__unknown__\",\"resazurin reduction viability/cytot... | 3.78 | 0.269863 | 0.786065 | 0.810883 | 0.786065 | 0.213935 | safety_canonical_v27 | 1 | true | 0.145631 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5M","__unknown__","resazurin reduction viability/cytotoxicity IC50 assay","L3"] | LUSHRJRLUBDDTB-KNQGVANASA-N | KXTNVBQRLRYVCO-OGHRFRAUSA-N | O=C1C=CC2C(CO1)CC(=O)C1C2CCC2C(C3=CCOC3=O)OC(=O)C3OC321 | O=C(C1=C2OCCCC23CCCC(C1=O)C3=O)c1ccccc1 | {
"aggregation_method": "individual_record",
"display_measurement_text": "5.77",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 5.77,
"aggregate_max": 5.77,
"aggregate_q1": 5.77,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "9.55",
"display_unit_text": "µM",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 9.55,
"aggregate_max": 9.55,
"aggregate_q1": 9.55,
"aggregate_... | 117 | 115 | 60 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":null,"assay_method":"resazurin reduction assay (RRA)","biological_test_system":"CCRF-CEM human leukemia cell line, in vitro","canonical_assay_context":"resazurin reduction viability/cytotoxicity IC50 assay","canonical_measurement_scale_id":"__unknown__","confidence":0.85,"effect_direc... | {"assay_interpretation_conditions":"Doxorubicin positive control.","assay_method":"resazurin cytotoxicity assay (IC50)","biological_test_system":"CCRF-CEM human T-lymphoblast leukemia cell line, in vitro","canonical_assay_context":"resazurin reduction viability/cytotoxicity IC50 assay","canonical_measurement_scale_id":... | L3 | gold_v1 | sr_e5e3b07000e64cb7bfe43417d1da4af1 | sr_231e1930af0e4d549388e09f5b49d25a | ["carcinogens_v1","cell viability or survival","µM","__unknown__","resazurin reduction viability/cytotoxicity IC50 assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>O=[N+]([O-])c1cc(S(=O)(=O)n2cc(CO)c3ccccc32)ccc1Cl</SMILES>
- Assay method: MTT assay
- Biological test system: PC-3 (p53-/- androgen-nonresponsive) prostate cancer cells, in vi... | (B) | train | d25a576d95dc7fe8fab767cc6fd20464b2cbd3a8ca62c055f55d6860216a4787 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:19efd5a8e468ec42ca4bc8f62d7c4b675b265a0c49cf931d960491782271a2ed | carcinogens:e061bc2f4c93c1efd0e114b6a5b74bf6694e079fdb8101ca6185b02ab79a3550 | carcinogens:19efd5a8e468ec42ca4bc8f62d7c4b675b265a0c49cf931d960491782271a2ed | carcinogens:e061bc2f4c93c1efd0e114b6a5b74bf6694e079fdb8101ca6185b02ab79a3550 | IVYPNXXAYMYVSP-UHFFFAOYSA-N | SBVMSMUUVDMKQT-UHFFFAOYSA-N | OCc1c[nH]c2ccccc12 | O=[N+]([O-])c1cc(S(=O)(=O)n2cc(CO)c3ccccc32)ccc1Cl | ["carcinogens_v1","cell viability or survival","\u00b5mol/L","__unknown__","MTT cell viability/proliferation assay","L3"] | ["carcinogens_v1","cell viability or survival","\u00b5mol/L","__unknown__","MTT cell viability/proliferation assay","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_method=MTT assay",
"biological_test_system=LNCaP (p53+/+ androgen-responsive) prostate cancer cells, in vitro",
"canonical_assay_context=MTT cell viability/proliferation assay",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50 for cell viability",
"endpoint_name=cell_viability_o... | [
"assay_method=MTT assay",
"biological_test_system=PC-3 (p53-/- androgen-nonresponsive) prostate cancer cells, in vitro",
"canonical_assay_context=MTT cell viability/proliferation assay",
"canonical_measurement_scale_id=__unknown__",
"endpoint_measure=IC50 for cell viability",
"endpoint_name=cell_viability... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | far | 2.426511 | 0.30103 | 2.125481 | 0.903753 | {
"nontransfer": 0.9999999966636309,
"transfer": 3.336369072409085e-9
} | ["carcinogens_v1","cell viability or survival","\u00b5mol/L","__unknown__","MTT cell viability/proliferation assay","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"cell viability or survival\",\"\\u00b5mol/L\",\"__unknown__\",\"MTT cell viability/proliferatio... | 265 | 2.351838 | 0 | 0.903753 | 0 | 1 | safety_canonical_v27 | 0 | true | 0.226415 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","cell viability or survival","\u00b5mol/L","__unknown__","MTT cell viability/proliferation assay","L3"] | IVYPNXXAYMYVSP-UHFFFAOYSA-N | SBVMSMUUVDMKQT-UHFFFAOYSA-N | c1ccc2[nH]ccc2c1 | O=S(=O)(c1ccccc1)n1ccc2ccccc21 | {
"aggregation_method": "individual_record",
"display_measurement_text": "267",
"display_unit_text": "µmol/L",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 267,
"aggregate_max": 267,
"aggregate_q1": 267,
"aggregate_... | {
"aggregation_method": "individual_record",
"display_measurement_text": "2",
"display_unit_text": "µmol/L",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 2,
"aggregate_max": 2,
"aggregate_q1": 2,
"aggregate_q3": 2
} | 33 | 33 | 21 | id | train_exact_bucket.v27_safety | log10 | {"assay_interpretation_conditions":null,"assay_method":"MTT assay","biological_test_system":"LNCaP (p53+/+ androgen-responsive) prostate cancer cells, in vitro","canonical_assay_context":"MTT cell viability/proliferation assay","canonical_measurement_scale_id":"__unknown__","confidence":0.85,"effect_direction":"decreas... | {"assay_interpretation_conditions":null,"assay_method":"MTT assay","biological_test_system":"PC-3 (p53-/- androgen-nonresponsive) prostate cancer cells, in vitro","canonical_assay_context":"MTT cell viability/proliferation assay","canonical_measurement_scale_id":"__unknown__","confidence":0.9,"effect_direction":"decrea... | L3 | gold_v1 | sr_1cac514bcd9b45acadb37bf34230403a | sr_9b08383ce1d54b50b0617326143e855d | ["carcinogens_v1","cell viability or survival","µmol/L","__unknown__","MTT cell viability/proliferation assay"] | |
You are comparing two experiments selected from similar assays.
The experimental details may differ.
Experiment A (known measurement)
<SMILES>NP(=O)(O)N(CCCl)CCCl</SMILES>
- Assay interpretation conditions: Comparator is the untreated normal group (10.8% ± 0.83%). Concurrently evaluated rescue conditions: MSCs group 2... | (A) | train | 7fdc16fa1b3315201fd9e69e2e43019b31157620a8f5f915a3d885b142187899 | -1 | null | -1 | null | null | null | carcinogens | carcinogens_v1 | limited_balanced_parent_morgan_first.v28_safety | carcinogens:23af59348c9629e038ff224fb1a103c461f4928df729aaefb7a8f9c1b9c88b18 | carcinogens:007906a7feaeb2cfd2d287d63712fbeb805dc54a703f1b83e692e7ff48ec9a19 | carcinogens:23af59348c9629e038ff224fb1a103c461f4928df729aaefb7a8f9c1b9c88b18 | carcinogens:007906a7feaeb2cfd2d287d63712fbeb805dc54a703f1b83e692e7ff48ec9a19 | MPBVHIBUJCELCL-UHFFFAOYSA-N | RJXQSIKBGKVNRT-UHFFFAOYSA-N | CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O | NP(=O)(O)N(CCCl)CCCl | ["carcinogens_v1","apoptosis","percent of cells","__unknown__","Annexin V flow cytometry - apoptosis","L3"] | ["carcinogens_v1","apoptosis","percent of cells","__unknown__","Annexin V flow cytometry - apoptosis","L3"] | exact_v10_pair_bucket_and_level | exact_v10_pair_bucket_and_level | [
"assay_interpretation_conditions=Apoptosis induction is Ca2+-dependent, observed at 1.6 mM Ca2+",
"assay_method=annexin V-PE staining, percentage of apoptotic (annexin V-PE-positive) cells",
"biological_test_system=In vitro; MCF-7 breast cancer cell line; Homo sapiens; cancer cell baseline state",
"canonical_... | [
"assay_interpretation_conditions=Comparator is the untreated normal group (10.8% ± 0.83%). Concurrently evaluated rescue conditions: MSCs group 28.2% ± 1.48% and heat-shock (HS)-pretreated MSC group 21.2% ± 2.28%, i.e., HS-pretreated MSCs reduced the phosphamide mustard-induced GC apoptosis rate relative to plain M... | same_exact_v10_pair_bucket_and_level | 1 | 1 | null | null | null | null | near | 32.9 | 33 | 0.1 | 23.043947 | {
"nontransfer": 0.01876893881232433,
"transfer": 0.9812310611876757
} | ["carcinogens_v1","apoptosis","percent of cells","__unknown__","Annexin V flow cytometry - apoptosis","L3"] | L3 | continuous | {
"calibration_sha256": "f3dd0fee05ce70816b449a0f900efce7f2a35db53faecc8350cad75feb598e8f",
"groups": {
"assay_concept": "L3",
"measurement_kind": "continuous",
"query_condition_group": "[\"carcinogens_v1\",\"apoptosis\",\"percent of cells\",\"__unknown__\",\"Annexin V flow cytometry - apoptosis\",\"L3\... | 0.1 | 0.00434 | 0.981231 | 23.043947 | 0.981231 | 0.018769 | safety_canonical_v27 | 1 | true | 0.205128 | -1 | -1 | -1 | indirect_record | ["carcinogens_v1","apoptosis","percent of cells","__unknown__","Annexin V flow cytometry - apoptosis","L3"] | MPBVHIBUJCELCL-UHFFFAOYSA-N | RJXQSIKBGKVNRT-UHFFFAOYSA-N | parent:MPBVHIBUJCELCL-UHFFFAOYSA-N | parent:RJXQSIKBGKVNRT-UHFFFAOYSA-N | {
"aggregation_method": "individual_record",
"display_measurement_text": "32.9",
"display_unit_text": "percent of cells",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 32.9,
"aggregate_max": 32.9,
"aggregate_q1": 32.9,... | {
"aggregation_method": "individual_record",
"display_measurement_text": "33",
"display_unit_text": "percent of cells",
"display_transform_id": "canonical_stage3.v10",
"source_record_count": 1,
"deduplicated_source_record_count": 1,
"aggregate_min": 33,
"aggregate_max": 33,
"aggregate_q1": 33,
"aggr... | 40 | 39 | 34 | id | train_exact_bucket.v27_safety | identity | {"assay_interpretation_conditions":"Apoptosis induction is Ca2+-dependent, observed at 1.6 mM Ca2+","assay_method":"annexin V-PE staining, percentage of apoptotic (annexin V-PE-positive) cells","biological_test_system":"In vitro; MCF-7 breast cancer cell line; Homo sapiens; cancer cell baseline state","canonical_assay_... | {"assay_interpretation_conditions":"Comparator is the untreated normal group (10.8% \u00b1 0.83%). Concurrently evaluated rescue conditions: MSCs group 28.2% \u00b1 1.48% and heat-shock (HS)-pretreated MSC group 21.2% \u00b1 2.28%, i.e., HS-pretreated MSCs reduced the phosphamide mustard-induced GC apoptosis rate relat... | L3 | gold_v1 | sr_424d31b41eb947e6ad2d507e89ca5077 | sr_b57e5b54b3c141869b79cef41caa2303 | ["carcinogens_v1","apoptosis","percent of cells","__unknown__","Annexin V flow cytometry - apoptosis"] |
End of preview. Expand in Data Studio
Carcinogens record-level V27 L3
This level-specific release uses current V10 physical evidence, the active Gold-owned level mapping, and Gold-v1 parent-disjoint evaluation. Undefined variance ratios are allowed; defined ratios above 0.65 are excluded. Prompts display canonical Stage-3 measurement and unit pairs.
Rows: {'train': 157901, 'validation_ranking': 22328, 'test_ranking': 16627}
- Downloads last month
- 42